UNSPSC 51313802: Fexofenadine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C32H39NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2S068B75ZU, chemically known as 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester but generally known as fexofenadine hydrochloride, which bears US NIH Compound Identifier 3333. European Medicines Agency schedules Fexofenadine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13884MIG.

UNSPSC 51313802 Fexofenadine hydrochloride is a Commodity code that in recent state and local procurement activity does not appear to represent what is actually being bought. The three most recent opportunities posted under this code involve naloxone and drug deactivation systems, a direct-to-manufacturer pharmacy initiative program design, and generic multi-source pharmaceuticals and over-the-counter products procured through a cooperative purchasing vehicle — none of which are fexofenadine hydrochloride specifically or even antihistamine medications in the scope of recent solicitation activity. The mismatch suggests either data-entry error in the state and local procurement systems or use of a catch-all commodity code by issuing bodies that do not granularly classify pharmaceutical products. The code shows minimal recent activity decision-relevant to fexofenadine hydrochloride supply.

The issuing bodies span a county health department, a state health and human services commission, and a multistate cooperative purchasing alliance administered by a state department of administration — indicating fragmented sourcing across different government health and procurement infrastructure. Seminole County, Florida (IFB60459723LAS, due July 26, 2023) sought naloxone and drug deactivation systems on an IFB notice with annual volumes and quarterly delivery; the Texas Health and Human Services Commission (HHS0017013, RFI posted April 3, 2026) issued an exploratory RFI to gather vendor capabilities for direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (S1070000015802, RFP due March 26, 2026) sought generic pharmaceuticals and OTC products through authorized wholesalers effective July 1, 2026. The geographic spread includes Florida, Texas, and Minnesota with multistate reach through the cooperative vehicle, but the pharmaceutical products named do not align with fexofenadine hydrochloride procurement.